ERNA — Ernexa Therapeutics Balance Sheet
0.000.00%
- $12.45m
- $10.72m
- $0.58m
Annual balance sheet for Ernexa Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K/A | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash | |||||
Cash and Equivalents | |||||
Cash and Short Term Investments | 0.777 | 17 | 11.4 | 7.58 | 1.73 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 0.116 | 0.684 | 0.951 | 0.425 | 0.437 |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 1.72 | 18.8 | 13.7 | 9.6 | 2.35 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 0.538 | 4.24 | 1.32 | 33.3 | 0.755 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 3.75 | 31.5 | 22.3 | 49.1 | 5.27 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 2.36 | 3.68 | 7.65 | 6.57 | 2.94 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 2.89 | 6.02 | 10.2 | 46.9 | 3.57 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 0.851 | 25.5 | 12.1 | 2.23 | 1.7 |
Total Liabilities & Shareholders' Equity | 3.75 | 31.5 | 22.3 | 49.1 | 5.27 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |